Studies demonstrated that incorporating STAT3/STAT5-binding domains within the cytoplasmic region of anti-CD19 CARs in conventional T cells significantly enhanced their in vivo persistence and anti-tumor efficacy (212). Here, CD19 is linked to neoplasm.